1
|
Hatta D, Makiya S, Kanamoto K, Watanabe K, Fuchigami Y, Kawakami S, Kinoshita A, Yoshiura KI, Kurotaki N, Shirotani K, Iwata N. Proline-rich transmembrane protein 2 regulates the magnitude and frequency of dopamine release by repetitive neuronal stimuli in the striatum of L-dopa-treated mice. Neuropsychopharmacol Rep 2024. [PMID: 39196683 DOI: 10.1002/npr2.12478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2024] [Revised: 08/11/2024] [Accepted: 08/14/2024] [Indexed: 08/30/2024] Open
Abstract
Mutations in proline-rich transmembrane protein 2 (PRRT2) cause paroxysmal kinesigenic dyskinesia (PKD). Recently, we reported that a Prrt2 mutation exacerbated L-dopa-induced motor deficits in mice, suggesting that the basal ganglia might contribute to PKD pathology. Here, we demonstrated that the Prrt2 mutation enhanced depolarization stimuli-induced extracellular dopamine levels in the mouse striatum, which were attenuated by repeated stimulation. L-dopa administration maintained high dopamine levels in Prrt2-KI mice even during repetitive stimuli but did not affect dopamine levels in wild-type mice. Thus, the enhanced and prolonged responsiveness of dopamine release in nigrostriatal dopaminergic neurons to sequential excitation may be partially implicated in Prrt2-related dyskinesia.
Collapse
Affiliation(s)
- Daisuke Hatta
- Department of Genome-Based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Shiho Makiya
- Department of Genome-Based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Kaito Kanamoto
- Department of Genome-Based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Kaori Watanabe
- Department of Genome-Based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Yuki Fuchigami
- Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Shigeru Kawakami
- Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Akira Kinoshita
- Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Koh-Ichiro Yoshiura
- Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Naohiro Kurotaki
- Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Keiro Shirotani
- Department of Genome-Based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Nobuhisa Iwata
- Department of Genome-Based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| |
Collapse
|